IPA by design

Modern therapeutic discovery campaigns must not only address the needs of our partners indications and modes of action, but also produce clinical lead candidates that are compatible and developable within the constraints of next generation scaffolds or payloads. IPA can create, characterize, engineer, and profile large panels of sequence and functionally diverse monoclonal antibodies. In addition, IPA has embedded in silico technology into its multi-species, multi-immunization, multi-platform approach to create an unmatched platform for discovery options and program designs.

There is more to a blockbuster drug than the drug itself. Much like the large and diverse teams that work together to bring today's therapeutics to market, therapeutic companion antibodies are integral components of the drug discovery process, with distinct roles and specifications. Whether anti-idiotypic, IHC, surrogate, or validation tools are required, IPA has the appropriate species and platform to get the job done right, the first time.

IPA has a long and trusted history of providing diagnostic partners with the highly specific, antibody or antibody pairs their assays require. We are preferred partners in discovering and manufacturing antibodies for immunohistochemistry, point-of-care lateral flow assays, in vitro clinical diagnostics (IVD), mass spectrometry based IVD, western blots and ELISA assays. From biomarkers to small molecules, IPA is highly skilled in producing antibodies with the required traits: no-cross-reactivity, low background, and enhanced detection.

Mammalian protein expression and purification services tailored to your needs. Expression and production workflows are designed to deliver recombinant proteins and antibodies for research and pre-clinical applications. Antibodies can be manufactured from a transient expression system, from stable cell lines or from hybridoma culture or animal sera.